A service of

Lorient leverages data to fill operational gaps in healthcare

  • Tech-enabled operating playbook scales lower mid-market companies
  • USD 503m Fund III has made six investments, two more expected
  • Thematic approach spans longevity, logistics, behavioral health, pediatrics, equipment repair

During a customary pre-close planning call, David Berman and Jordan Broome, managing partners of Lorient, sat down with the founder of a fast-growing healthcare provider to demo the private equity firm’s proprietary data platform.

The founder, a physician who had been running his business with the help of a fax machine, was amazed by what he saw.

Broome

“The only question we got after a long silence was, ‘What do I do with the rest of my day?’,” Broome told Mergermarket.

The exchange speaks to a US healthcare market that remains surprisingly analog despite its colossal size. National healthcare expenditure reached USD 5.3tn in 2024, representing approximately 18% of gross domestic product (GDP), according to the Centers for Medicare & Medicaid Services (CMS).

Yet Lorient frequently encounters businesses that still rely on fax reports and paper records. To fill the inevitable gaps, it developed Morpheus. The platform aggregates data from more than 40 software solutions into a centralized data warehouse as part of a framework the Miami-based sponsor calls L1OS – short for Lorient Operating System.

L1OS and Morpheus are the pillars of a data-led approach that has seen Lorient grow from a deal-by-deal investor into a healthcare specialist currently deploying its third fund, which closed on USD 503m last year.  So far, the vehicle has made six investments out of an expected eight, including the acquisition of PeterMD, a direct-to-consumer health optimization platform, earlier this year.

The focus is on control investments in healthcare providers, healthcare services and healthcare technology with USD 5m-USD 25m in EBITDA that need operational and technological support to get to the next level.

“We’re looking for businesses where there’s a great product or service that is suffering from inflection points we know how to fix,” Broome said.

Gradual origins

That thesis was years in the making.

For Broome, whose mother was a speech-language pathologist, the realization that healthcare was lacking in technology dawned early. The idea further crystallized after he connected with Berman while working at healthcare-focused investment bank Ziegler in the early 2010s.

Berman

The job involved long shifts analyzing founder-owned companies where paper and PDFs were the norm and they had to pull together fragmented datasets. “Data became part of our DNA,” Berman said.

After leaving Ziegler, Berman relocated to Detroit to work for Centene; he had previously sold a business to the New York-listed managed care organization. Meanwhile, Broome joined an Ohio-based home care provider, where he served as vice president of finance and operations and later CFO. When that company was sold to a larger competitor, it clarified the universal nature of the sector’s challenges.

“What I found when I got into the business was that the mom-and-pop operators we see at the lower end of the middle market aren’t all that different from some of the larger players,” Broome said. “There are still a lot of inefficiencies on both sides.”

In mid-2015, Berman called to propose a long overdue catch-up. He planned to float the idea of launching a firm that would invest in lower middle market healthcare companies and help them grow into regional leaders. “I convinced him to come up to Michigan for a weekend,” said Berman.

By the end of the trip, the pair had decided to launch Lorient. The firm raised capital on a deal-by-deal basis for its first six investments and closed its debut fund on USD 122m in 2018. A second vehicle raised USD 225m three years later. Fund III closed on USD 503m last year.

The LP base is a mix of fund-of-funds, endowments, foundations, public pensions, insurance companies and family offices, including both US and international institutions. The majority of non-US LPs are based in Europe, with some in South America.

Sourcing funnel 

From the start, the emphasis has been on founder-owned healthcare businesses that are scaling rapidly but lack visibility in their operations.

To identify these companies, Lorient takes a thematic approach. It has an active library of around 270 investment themes, prioritizing 10-15 a year. The business development team conducts eight to sixteen weeks of founder outreach and validation before resources are committed to a theme.

The playing field is vast and fragmented. Longevity, third-party logistics, behavioral health, pediatric nursing and medical equipment repair are on the priority list currently, while the firm is also interested in repeat investments in urgent care, primary care and home health.

“Honestly, we could spend the next hundred years investing in these sectors and still barely make a dent,” Broome said.

The sourcing funnel is narrow, however. Lorient contacts roughly 1,000 companies for each theme. Of those, only 100 make it into the active pipeline, usually culminating in a single deal.

PeterMD, a telehealth hormone replacement therapy platform serving primarily men, is a case in point. The deal originated from a broader thesis around longevity that the firm began exploring in 2024, based on the idea that consumers were taking greater ownership of their healthcare outcomes.

Areas such as concierge medicine, longevity clinics and supplements were considered, but Lorient observed particularly strong demand in hormone replacement therapy. Around a dozen companies in the field were evaluated before investing in PeterMD in February.

Technology plays a key role. Lorient uses web scraping, data enrichment and marketing automation tools and has built three proprietary company databases.

There is still plenty of room for old-school hustle. Sourcing and business development is led by James Thornton, now a partner, who joined the firm in 2018 after impressing Berman during his job interview when he secured a meeting with an autism services CEO from a cold call.

Relationship-building is arguably just as important. Sales cycles in healthcare are lengthy, so it helps to get in front of founders as early as possible. “It can take eight years for us to build a relationship with a founder before they’re ready to do something with us,” Broome said.

The 2023 buyout of urgent and primary care services provider Midwest Express illustrates the point. Initial contact was made five years earlier – again via a cold call – by Doug Shinkle, a partner, who joined as an associate during the deployment of Fund I.

Top quartile

Midwest Express also showcases Lorient’s value creation playbook, which starts with identifying potential for growth. The company had grown from around a dozen to 35 locations between the time of Shinkle’s first call and the eventual investment. The spurt saw patient volumes rise to roughly double those of many urgent care peers.

Still, Lorient spotted revenue cycle inefficiencies, in part by using Morpheus. Midwest Express was collecting 95%-96% of what its insurance contracts stipulated it was owed. The discrepancies came down to paperwork – a missing signature, a form that wasn’t filled out completely or documentation that wasn’t clear.

“They were doing all the right work,” Broome said. “They were providing the care. They just weren’t getting paid correctly for it.”

New wellness and pediatric services were launched, while the clinic count has expanded to 67 across the broader Chicagoland area. Most of the growth has been achieved organically – through de novo locations – rather than through acquisitions, which is typical for Lorient.

Portfolio-wide, the sponsor claims that two-thirds of growth has been organic, with just a third coming from M&A. In total, it has helped open more than 200 de novo locations across approximately 20 platforms. This has come with significant talent recruitment support. Lorient has placed more than 170 employees, including executives, into portfolio companies with an 80% retention rate.

Broadly, the approach is often about finding marginal gains that add up to make a big difference – 1% at a time.

“The contrarian part about it is, it doesn’t mean we cut costs,” said Broome. “We actually never cut costs. We’re always making investments.”

Operating system

All portfolio companies are plugged into L1OS, the product of a years-long development effort. Lorient’s Detroit origins played a significant role; the system draws from the Lean and Six Sigma process improvement methodologies that are prevalent in the city’s automotive and manufacturing industries.

L10S is built around five performance domains: volume, productivity, quality, utilization and unit economics. According to Broome, the goal is to create something that is programmatic, repeatable and, ideally, predictable.

“To create consistent outcomes, you have to have consistency in the process, the management systems, the actual systems at the portfolio companies and the data structure,” he explained.

Morpheus is the engine that binds everything together. Claude has been integrated into the platform through a custom MCP [model context protocol] connection. Since February, portfolio company management teams have been able to access an AI system that can identify opportunities, create performance improvement plans and analyze operational bottlenecks.

“Now the CEO can go into Claude and ask, ‘What are my top 10 opportunities? Why isn’t my revenue cycle management performing?'” said Berman, adding that L1OS allows all portfolio companies to run on the same set of systems, with the same underlying data architecture and same management applications.

Recent examples of the operating system in action include autism specialist Behavior Frontiers, which was acquired in 2020 after a review of more than 300 companies in the segment. The company, then around 15 years old, employed roughly 800 people but was still operating largely without centralized financial and operational infrastructure.

Lorient worked with management to build an over 100-strong team supporting recruiting, scheduling, intake, finance and revenue cycle functions. Approximately 30 de novo centers were opened, while a proprietary clinical technology platform known as PrioraCare was developed.

These investments did not come at the expense of care quality. According to a press release, which cites PrioraCare data, patients demonstrated significant gains in communication and developmental skills, while severe behaviors and aggression were reduced by 60% and 69%, respectively. The company treated Broome’s own nephew, he noted.

Exit paths

By the time Behavior Frontiers was sold to NexPhase Capital last year, it had a waitlist twice the size of its active operations. For Berman, when things are going that well, it is often a sign that the time is right to exit.

“Usually the best time to sell is when you don’t want to sell,” he said. “The company’s growing like crazy and the management team is executing. We did the heavy lifting in the early years, so now we can step back and act as advisors.”

Lorient has nine exits to date. While it sees continuation vehicles (CVs) as a useful tool, traditional M&A exits are preferred, with the primary buyer universe consisting of larger private equity firms and strategic acquirers. The average holding period is less than four years.

Looking ahead, investment in operating infrastructure will remain a key priority. One area of focus is the CXO program, which places chiefs of staff in portfolio companies and looks to grow the next generation of healthcare executives.

Meanwhile, there are plans to further invest in AI capability, which the firm sees as another building block on the data foundations laid with L1OS and Morpheus.

“We were fortunate that we had great data, but it wasn’t luck,” said Broome. “We’ve been data-oriented for years, so when AI arrived, we were ready.”